SCHEMBL4331928

SCHEMBL4331928

Cc1cccc(-c2noc(NC(=O)CCc3ccccc3)c2-c2ccncc2)c1C

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 10/20 0.67
POLB P06746 1/20 0.49
LMNA P02545 1/20 0.46
ALDH1A1 P00352 3/20 0.42
ALOX12 P18054 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
MLYCD O95822 1/20 0.42
HCAR2 Q8TDS4 1/20 0.41
P2RX7 Q99572 1/20 0.40
KDM6B O15054 1/20 0.40
KDM4D Q6B0I6 1/20 0.40
KDM4C Q9H3R0 1/20 0.40
EGLN3 Q9H6Z9 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
NPY5R Q15761 1/20 0.40
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4336205 0.93 MAPK14 (0.70) MAPK14POLBLMNAALDH1A1MLYCD
SCHEMBL4341812 0.90 MAPK14 (0.66) MAPK14HPGD
SCHEMBL4341498 0.90 MAPK14 (0.54) MAPK14POLBLMNA
SCHEMBL4339271 0.88 MAPK14 (0.52) MAPK14ALDH1A1
SCHEMBL4339508 0.86 MAPK14 (0.66) MAPK14LMNASMN1; SMN2MLYCDHCAR2
SCHEMBL4334980 0.86 MAPK14 (0.88) MAPK14LMNASMN1; SMN2MLYCDHCAR2
SCHEMBL4482965 0.85 MAPK14 (0.68) MAPK14LMNAALDH1A1SMN1; SMN2KDM6B
SCHEMBL4330108 0.85 MAPK14 (0.69) MAPK14LMNAALDH1A1SMN1; SMN2HPGD
SCHEMBL4333453 0.85 MAPK14 (0.72) MAPK14LMNASMN1; SMN2MLYCDKDM6B
SCHEMBL4341935 0.84 MAPK14 (0.75) MAPK14LMNAALDH1A1MLYCDHCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2036905-B1 PYRIDYLISOXAZOLE DERIVATIVE ASKA PHARM CO LTD (JP) 2012-12-12 EP disclosed
US-8207203-B2 Pyridylisoxazole derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-06-26 US disclosed
US-20090306145-A1 Pyridylisoxazole Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
EP-2036905-A1 PYRIDYLISOXAZOLE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2009-03-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306145-A1 Pyridylisoxazole Derivatives CNKSR1, MAPK1, MAPK3 MAPK14 43/4885POLB 3172/4885LMNA 4792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.